公开(公告)号：EP2968497B1

公开(公告)日：2020-08-12

申请号：EP14764623.6

申请日：2014-03-14

申请人： Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center ,  Novadigm Therapeutics, Inc.

发明人： IBRAHIM, Ashraf, S. ,  YEAMAN, Michael, R. ,  FILLER, Scott, G. ,  EDWARDS, John, E., Jr. ,  HENNESSEY, John, P., Jr.

IPC分类号： A61K39/00 ,  A61K39/38

公开(公告)号：EP2755668A2

公开(公告)日：2014-07-23

申请号：EP12832321.9

申请日：2012-09-14

申请人： Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

发明人： IBRAHIM, Ashraf, S. ,  YEAMAN, Michael, R. ,  EDWARDS, John, E., Jr. ,  LUO, Guanpingsheng ,  FU, Yue

IPC分类号： A61K36/06 ,  C07K14/00 ,  A61K38/00 ,  C12Q1/68

CPC分类号： C07K14/40 ,  A61K39/00 ,  A61K39/0002 ,  A61K47/646 ,  A61K2039/6081 ,  C07K16/14

摘要： The invention features isolated polypeptides of Hyrl. The invention further features vaccines and antibodies useful in treating or preventing candidiasis or Acinetobacter infections or both.

公开(公告)号：EP2968497A2

公开(公告)日：2016-01-20

申请号：EP14764623.6

申请日：2014-03-14

申请人： Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center ,  Novadigm Therapeutics, Inc.

发明人： IBRAHIM, Ashraf, S. ,  YEAMAN, Michael, R. ,  FILLER, Scott, G. ,  EDWARDS, John, E., Jr. ,  HENNESSEY, John, P., Jr.

IPC分类号： A61K39/00 ,  A61K39/38

摘要： The invention features fragments of the Candida cell surface proteins Als3 and Hyr1 and combinations thereof useful in immunizing a subject against fungal or bacterial infections or both.

摘要翻译： 本发明提供了念珠菌细胞表面蛋白Als3和Hyr1的片段以及它们的组合，可用于免疫受试者抵抗真菌或细菌感染或两者。

公开(公告)号：EP2734229A1

公开(公告)日：2014-05-28

申请号：EP12817530.4

申请日：2012-07-20

申请人： Novadigm Therapeutics, Inc. ,  Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

发明人： YEAMAN, Michael, R. ,  EDWARDS, John, E., Jr. ,  FILLER, Scott, G. ,  IBRAHIM, Ashraf, S ,  FU, Yue ,  HENNESSEY, John, P., Jr.

IPC分类号： A61K39/00

CPC分类号： A61K39/0002 ,  A61K45/06 ,  A61K2039/55505 ,  A61K2039/58

摘要： The invention features a method of vaccinating a mammal against
Staphylococcus aureus which includes the steps of: a) identifying a mammal at risk for the development of a
Staphylococcus aureus skin or soft tissue infection; and b) administering to said mammal an immunogenic amount of a vaccine that includes a polypeptide including an isolated agglutinin-like sequence (Als) 3 protein (Als3p), or an immunogenic fragment thereof, in a pharmaceutically acceptable medium.

公开(公告)号：EP2734229B1

公开(公告)日：2019-01-02

申请号：EP12817530.4

申请日：2012-07-20

申请人： Novadigm Therapeutics, Inc. ,  Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

发明人： YEAMAN, Michael, R. ,  EDWARDS, John, E., Jr. ,  FILLER, Scott, G. ,  IBRAHIM, Ashraf, S ,  FU, Yue ,  HENNESSEY, John, P., Jr.

IPC分类号： A61K45/06 ,  A61K39/00